The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead
Analysts are anticipating that Merck will soon have a new write-down to add to the $3 billion fine the pharma giant recorded earlier this year when it discounted its big hep C drug MK-3682.
The pharma giant said this morning that it is dropping two key combos — MK3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK3682C (ruzasvir/uprifosbuvir) — that were seen as successors to its struggling franchise for Zepatier.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
